The therapeutics of migraine.
This paper reviews the therapeutics of migraine in the context of the clinical problem and its prevalence. General principles of pharmacotherapy for symptomatic and preventive medications are provided. Two new drugs, sumatriptan (recommended for acute symptomatic therapy), and valproic acid (recommended for migraine prevention), are reviewed. The clinical effectiveness and the mechanisms of action of these drugs are discussed.
Department of Neurology, Henry Ford Hospital and Health Sciences Center, Detroit, MI 48202.
K M
KM
Welch
D001921:Brain / Q000098:blood supply; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy*; D009474:Neurons / Q000187:drug effects; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D018170:Sumatriptan; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D014661:Vasoconstriction / Q000187:drug effects
D007211:Indoles; D017366:Serotonin Receptor Agonists; D013449:Sulfonamides; D014635:Valproic Acid; D018170:Sumatriptan